RAPPORT THERAPEUTICS INC
RAPP
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Rapport Therapeutics is a clinical-stage biopharmaceutical company whose business model requires animal testing for drug development and regulatory approval. The company’s lead candidate, RAP-219, is being developed for epilepsy and bipolar mania, and its advancement through Phase 2a and planned Phase 3 trials necessitates extensive preclinical animal studies to demonstrate safety and efficacy, as mandated by the U.S. Food and Drug Administration. This reliance on animal models is inherent to its core pharmaceutical research and development operations.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.